Form 4: PharmaCyte Director's Stock & Option Activity

PharmaCyte Biotech Director Wayne Walker reported acquiring common stock and stock options, alongside a tax-related disposition of shares.

Summary

• Director Wayne Remell Walker reported transactions in PharmaCyte Biotech, Inc. (PMCB) common stock and stock options.
• On December 12, 2025, Mr. Walker acquired 37,500 shares of common stock at a price of $0.
• On the same date, 16,875 shares of common stock were disposed of at $1.02 per share, representing shares withheld by the Issuer to satisfy tax liability upon vesting of restricted stock units, and not an open-market sale.
• Following these transactions, Mr. Walker directly beneficially owns 20,625 shares of common stock.
• On April 25, 2025, Mr. Walker was granted 63,233 stock options (right to buy) with an exercise price of $1.22.
• These options will vest in full on the date of the Issuer's next annual meeting of stockholders, subject to Mr. Walker's continued service.
• The options have an expiration date of April 24, 2035.
• The filing of this transaction was late due to an inadvertent administrative error.

Sentiment

Score: 6

Explanation: The acquisition of common stock and a significant number of stock options by a director suggests confidence in the company's future. While there was a disposition of shares, it was for tax purposes and not an open-market sale, mitigating negative sentiment. The late filing is a minor administrative issue.

Positives

• Director Wayne Remell Walker acquired 37,500 shares of common stock at $0, increasing his direct ownership.
• Mr. Walker was granted 63,233 stock options, indicating potential future upside tied to the company's performance and his continued service.

Negatives

• 16,875 shares of common stock were disposed of to cover tax liabilities, reducing the overall beneficial ownership from the acquired shares.
• The transaction filing was late due to an inadvertent administrative error, which could be seen as a minor governance oversight.

Risks

• The vesting of the 63,233 stock options is contingent on Mr. Walker's continued service until the next annual meeting of stockholders.
• The late filing due to an administrative error, while explained, indicates a minor procedural lapse.

Future Outlook

The 63,233 stock options granted to Director Wayne Remell Walker are set to vest in full on the date of PharmaCyte Biotech's next annual meeting of stockholders, provided he continues his service to the company.

Management Comments

• "Represents shares withheld by the Issuer to satisfy the tax liability upon vesting of restricted stock units and does not constitute an actual sale or other open-market transaction."
• "The options shall vest in full on the date of the Issuer's next annual meeting of stockholders, subject to the continued service of Mr. Walker."
• "This transaction is late due to an inadvertent administrative error and not any error of Mr. Walker."

Industry Context

This Form 4 filing details routine insider transactions, specifically a director's acquisition of shares and options, alongside a tax-related share disposition. Such filings are standard disclosures in the biotechnology industry, providing transparency into executive and director holdings and their alignment with shareholder interests.

Comparison to Industry Standards

• Not applicable. This filing reports specific insider transactions rather than company performance metrics that could be benchmarked against industry peers.

Stakeholder Impact

• Shareholders: The director's acquisition of shares and options may be viewed as a positive signal of management's belief in the company's future prospects. The tax-related disposition is a routine event.
• Employees: The vesting condition tied to continued service is standard for executive compensation.

Next Steps

• The vesting of 63,233 stock options will occur on the date of the Issuer's next annual meeting of stockholders, contingent on Mr. Walker's continued service.

Key Dates

Recommendation

The filing details routine insider transactions, including the acquisition of shares and options, alongside a tax-related disposition. While the acquisition of options and shares by a director can be seen as a positive signal, the overall activity is not significant enough to warrant a strong buy or sell recommendation. The late filing is a minor administrative issue. Investors should consider broader company fundamentals and market conditions rather than solely relying on this routine disclosure.

Keywords

PharmaCyte Biotech, PMCB, Form 4, insider trading, stock options, director, beneficial ownership